Marcelo Katz

Marcelo Katz

Auto-generated profile, based on publicly available information

Marcelo Katz

Hospital Israelita Albert Einstein, São Paulo, SP, Brazil

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
LALuciana V. Armaganijan
Luciana V. Armaganijan
RSRodolfo Staico
Rodolfo Staico
DMDalmo A.R. Moreira
Dalmo A.R. Moreira
RLRenato D. Lopes
Renato D. Lopes
PMPaulo T.J. Medeiros
Paulo T.J. Medeiros
AAAlexandre Abizaid
Alexandre Abizaid

18 July 2014 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
MKMarcelo Katz
Marcelo Katz
ALAntonio G Laurinavicius
Antonio G Laurinavicius
FFFabio Gm Franco
Fabio Gm Franco
RCRaquel D Conceicao
Raquel D Conceicao
JCJose Am Carvalho
Jose Am Carvalho
RSRaul D Santos
Raul D Santos
Poor adherence to medical treatment represents a major health problem. A subject’s misperception of his own cardiovascular risk has been indicated as a key driver for low compliance with preventive measures. This study analysed the relationship between objectively calculated short- and long-term cardiovascular risk and its subjective perception. Cross-sectional study in asymptomatic Brazilian subjects. Individuals (N = 6544, mean age 49.1 ± 7 years, 22.2% female) who underwent a routine mandatory health evaluation were studied. A questionnaire in which each individual rated his own cardiovascular risk as low, intermediate or high according to his own perception was used. The 10-year and lifetime cardiovascular risk were calculated respectively using the Framingham risk (FRS) and Lifetime risk (LRS) scores. Individuals were classified as hypo-perceivers (i.e. perceived risk lower than estimated risk), normo-perceivers (i.e. perceived risk coincident with estimated risk) and hyper-perceivers (i.e. perceived risk higher than estimated risk). Cardiovascular risk, using the FRS, was low in 77.9% (N = 5071), intermediate in 14.4% (N = 939) and high in 7.7% (N = 499) of subjects. Cardiovascular risk, using the LRS, was low in 7.6% (N = 492), intermediate in 43.1% (N = 2787) and high in 49.3% (N = 3184) of the study population. The prevalence of normo-perceivers was 57.6% using the FRS and only 20.6% using the LRS. Using the LRS, 72.3% of the intermediate and 91.2% of the high-risk subjects were hypo-perceivers. In a large sample of asymptomatic individuals, there was a gap between calculated and perceived cardiovascular risk. Using a long-term risk score, most of the intermediate- and high-risk subjects were hypo-perceivers.

29 July 2016 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
MKMarcelo Katz
Marcelo Katz
AFAntonio Carlos Bacelar Nunes Filho
Antonio Carlos Bacelar Nunes Filho
ACAdriano Caixeta
Adriano Caixeta
LCLuiz Antonio Carvalho
Luiz Antonio Carvalho
RSRogério Sarmento‐Leite
Rogério Sarmento‐Leite
OIOn behalf of the Brazilian TAVI Registry investigators
On behalf of the Brazilian TAVI Registry investigators

1 January 2015 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
LSLeonardo Sinnott Silva
Leonardo Sinnott Silva
PCPaulo Ricardo Avancini Caramori
Paulo Ricardo Avancini Caramori
AFAntonio Carlos Bacelar Nunes Filho
Antonio Carlos Bacelar Nunes Filho
MKMarcelo Katz
Marcelo Katz
JGJoão Carlos Vieira da Costa Guaragna
João Carlos Vieira da Costa Guaragna
FJFabio S. de Brito Júnior
Fabio S. de Brito Júnior
Predicting mortality in patients undergoing transcatheter aortic valve implantation (TAVI) remains a challenge. To evaluate the performance of 5 risk scores for cardiac surgery in predicting the 30-day mortality among patients of the Brazilian Registry of TAVI. The Brazilian Multicenter Registry prospectively enrolled 418 patients undergoing TAVI in 18 centers between 2008 and 2013. The 30-day mortality risk was calculated using the following surgical scores: the logistic EuroSCORE I (ESI), EuroSCORE II (ESII), Society of Thoracic Surgeons (STS) score, Ambler score (AS) and Guaragna score (GS). The performance of the risk scores was evaluated in terms of their calibration (Hosmer-Lemeshow test) and discrimination [area under the receiver-operating characteristic curve (AUC)]. The mean age was 81.5 ± 7.7 years. The CoreValve (Medtronic) was used in 86.1% of the cohort, and the transfemoral approach was used in 96.2%. The observed 30-day mortality was 9.1%. The 30-day mortality predicted by the scores was as follows: ESI, 20.2 ± 13.8%; ESII, 6.5 ± 13.8%; STS score, 14.7 ± 4.4%; AS, 7.0 ± 3.8%; GS, 17.3 ± 10.8%. Using AUC, none of the tested scores could accurately predict the 30-day mortality. AUC for the scores was as follows: 0.58 [95% confidence interval (CI): 0.49 to 0.68, p = 0.09] for ESI; 0.54 (95% CI: 0.44 to 0.64, p = 0.42) for ESII; 0.57 (95% CI: 0.47 to 0.67, p = 0.16) for AS; 0.48 (95% IC: 0.38 to 0.57, p = 0.68) for STS score; and 0.52 (95% CI: 0.42 to 0.62, p = 0.64) for GS. The Hosmer-Lemeshow test indicated acceptable calibration for all scores (p > 0.05). In this real world Brazilian registry, the surgical risk scores were inaccurate in predicting mortality after TAVI. Risk models specifically developed for TAVI are required.

5 June 2013 in Journal of Cardiovascular Pharmacology and Therapeutics
Verified
Journal Article
Closed access
PDF file
APAntonio Eduardo P. Pesaro
Antonio Eduardo P. Pesaro
CSCarlos V. Serrano
Carlos V. Serrano
MKMarcelo Katz
Marcelo Katz
LMLuciana Marti
Luciana Marti
JFJuliano L. Fernandes
Juliano L. Fernandes
ACAlexandre H. Campos
Alexandre H. Campos
Background: Patients with coronary artery disease (CAD) should be treated with statins to attain very low cholesterol levels, in order to reduce cardiovascular adverse events. More than 70% of these patients do not reach the appropriate cholesterol goal despite moderate statin doses. However, it is not known whether therapeutic uptitration with different lipid-lowering strategies has a similar “pleiotropic” effect on atherosclerotic endothelial dysfunction evaluated by measurement of endothelial progenitor cells (EPCs). Objective: We sought to compare, in patients with stable CAD and with a low-density lipoprotein cholesterol (LDL-C) >70 mg/dL on treatment with simvastatin 20 mg, the effects on EPCs by increasing simvastatin to 80 mg versus adding ezetimibe 10 mg. Methods: Patients (n = 68, 63 ± 9 years, 39% men) were randomly allocated to receive ezetimibe 10/simvastatin 20 mg or simvastatin 80 mg for 6 weeks. Circulating EPCs were measured by flow cytometry before and after the treatment. Results: Both strategies presented similar effects on metabolic parameters. The LDLs were equally reduced by ezetimibe 10/simvastatin 20 mg and simvastatin 80 mg (28.9% ± 13% vs 21.1% ± 33%; P = .46, respectively). The levels of EPCs were unaffected by ezetimibe 10/simvastatin 20 mg (median [25th, 75th]: pre- vs posttreatment, 7.0 [2.3; 13.3] vs 3.1 [0.1; 13.2] EPCs/104 mononuclear cells; P = .43) or simvastatin 80 mg (pre- vs posttreatment, 6.1 [2.9; 15.2] vs 4.0 [1.4; 10.7] EPCs/104 mononuclear cells; P = .5) ,and there were no differences between the groups on treatment effects ( P = .9). Conclusions: Among stable patients with CAD and with an LDL-C >70 mg/dL on simvastatin 20 mg, increasing simvastatin dose to 80 mg or adding ezetimibe 10 mg promoted similar further cholesterol reduction but did not have incremental effects on circulating EPCs. These data suggest that the effects of simvastatin moderate doses on EPCs are not increased by intensive lipid-lowering strategies (clinicaltrials.gov: NCT00474123).

25 February 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RCRicardo Casalino
Ricardo Casalino
FTFlávio Tarasoutchi
Flávio Tarasoutchi
GSGuilherme Spina
Guilherme Spina
MKMarcelo Katz
Marcelo Katz
ABAntonio Bacelar
Antonio Bacelar
MGMax Grinberg
Max Grinberg
Epidemiological differences can be found between Brazilian and European valvular heart disease patients. The prevalence of heart valve diseases due to rheumatic disease is significantly higher in the Brazilian compared with the European population. Therefore, they could have different risks during and after cardiac surgery. The aim of this study was to evaluate the applicability of the additive and logistic EuroSCORE and EuroSCORE II in a cohort of high-risk patients with valvular heart disease of predominantly rheumatic aetiology submitted to surgery. Between 1 February and 30 December 2009, 540 consecutive patients scheduled for valvular heart surgery were included in this study. In this set of patients, we examined the performance of the additive, logistic, and EuroSCORE II models for predicting in-hospital mortality. Calibration of each model was assessed by comparing predicted and observed in-hospital mortality and by the goodness of fit of the Hosmer-Lemeshow chi-square test. Discrimination performance of the model was evaluated with the receiver operating characteristic (ROC) curve analysis. The mean age was 56 ± 16 years, 50.6% were female, and the mortality rate was 16.0% (6.0% in elective surgery and 34.0% in emergency/urgency surgery). Mortality rates were estimated according to the additive and logistic EuroSCORE and EuroSCORE II at 6.1%, 8.7%, and 4.3%, respectively. The AUC was 0.76 (95% confidence interval [95% CI] 0.70–0.81) for the additive EuroSCORE, 0.76 (95% CI 0.70–0.81) for the logistic EuroSCORE and 0.81 (95% CI 0.76–0.86) for EuroSCORE II. Hosmer-Lemeshow goodness-of-fit statistics were P = 0.52, P = 0.07, and P = 0.12 for additive, logistic EuroSCORE, and EuroSCORE II. In this cohort of Brazilian patients with valvular heart disease submitted to surgical procedure, the EuroSCORE models had a good discriminatory capacity; however, the calibration was compromised because of an underestimation of the mortality rate.